Shares of Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) were down 7.6% on Thursday . The stock traded as low as $0.31 and last traded at $0.32. Approximately 19,046 shares traded hands during trading, a decline of 91% from the average daily volume of 204,750 shares. The stock had previously closed at $0.35.
Panbela Therapeutics Stock Performance
The firm has a 50-day moving average of $0.34 and a 200-day moving average of $0.36. The firm has a market capitalization of $1.56 million, a P/E ratio of 0.00 and a beta of 1.56.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
See Also
- Five stocks we like better than Panbela Therapeutics
- Energy and Oil Stocks Explained
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Find and Profitably Trade Stocks at 52-Week Lows
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
